Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Endocyte Company Profile (NASDAQ:ECYT)

Consensus Ratings for Endocyte (NASDAQ:ECYT) (?)
Ratings Breakdown: 5 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $24.49 (292.47% upside)

Current Analysts' Coverage Summary for Endocyte (NASDAQ:ECYT)
Show:
DateFirmActionRatingPrice TargetDetailsShare
9/30/2014ZacksDowngradeOutperform -> Neutral$8.40ViewTweet This Rating  Share This Rating on StockTwits
9/30/2014Brean CapitalDowngradeBuy -> HoldViewTweet This Rating  Share This Rating on StockTwits
9/29/2014Citigroup Inc.Reiterated RatingNeutral$8.00 -> $10.00ViewTweet This Rating  Share This Rating on StockTwits
9/25/2014Chardan CapitalReiterated RatingPositiveViewTweet This Rating  Share This Rating on StockTwits
9/8/2014Cantor FitzgeraldInitiated CoverageBuy$21.00ViewTweet This Rating  Share This Rating on StockTwits
6/18/2014RBC CapitalLower Price TargetOutperform$20.00 -> $15.00ViewTweet This Rating  Share This Rating on StockTwits
5/2/2014Piper JaffrayDowngradeOverweight -> Neutral$13.50ViewTweet This Rating  Share This Rating on StockTwits
5/2/2014Robert W. BairdDowngradeOutperform -> Neutral$36.00 -> $8.00ViewTweet This Rating  Share This Rating on StockTwits
3/25/2014WedbushReiterated RatingOutperform$23.00 -> $65.00ViewTweet This Rating  Share This Rating on StockTwits
3/24/2014Roth CapitalBoost Price Target$20.00 -> $42.00ViewTweet This Rating  Share This Rating on StockTwits
3/21/2014Credit SuisseBoost Price TargetOutperform$24.00 -> $44.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Leerink SwannLower Price Target$21.00 -> $18.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 12/20/2012 forward)